Apeloa Pharmaceutical Co.,Ltd (SHE:000739)

SHE:000739 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Sep 30, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020	Dec 31, 2019
Operating Revenue	12,230	11,440	10,506	8,910	7,852	7,198
Other Revenue	33.92	33.92	39.1	32.44	28.09	12.57
Revenue	12,264	11,474	10,545	8,943	7,880	7,211
Revenue Growth (YoY)	6.70%	8.81%	17.92%	13.49%	9.28%	13.09%
Cost of Revenue	9,437	8,621	8,075	6,579	5,700	4,910
Gross Profit	2,828	2,853	2,470	2,364	2,179	2,301
Selling, General & Admin	1,101	1,125	985.33	906.43	957.56	1,293
Research & Development	608.32	624.87	532.92	446.22	350.06	359.89
Other Operating Expenses	-18.93	23.3	31.76	33.05	38.83	44.42
Operating Expenses	1,691	1,775	1,563	1,405	1,356	1,697
Operating Income	1,137	1,078	906.8	959.39	823.59	603.45
Interest Expense	-38.91	-43.77	-59.23	-35.72	-16.01	-30.15
Interest & Investment Income	107.68	113.47	75.83	165.7	86.9	7.29
Currency Exchange Gain (Loss)	38.13	38.13	93.42	-23.09	-73.61	11.63
Other Non Operating Income (Expenses)	-72.73	-8.35	-5.38	-3.58	-2.33	-1.89
EBT Excluding Unusual Items	1,171	1,177	1,011	1,063	818.54	590.32
Impairment of Goodwill	-	-	-	-	-	-9.19
Gain (Loss) on Sale of Investments	5.89	-21.7	-82.61	-23.62	47.45	-30.62
Gain (Loss) on Sale of Assets	2.25	1.33	1.37	0.28	8.52	4.23
Asset Writedown	-19.12	-15.2	-4.67	-7.95	-10.2	-10.17
Other Unusual Items	59.65	62.93	86.52	82.67	96.85	89.15
Pretax Income	1,220	1,205	1,012	1,114	961.15	633.73
Income Tax Expense	146.41	149.34	22.89	158.53	144.42	80.33
Earnings From Continuing Operations	1,073	1,055	989.17	955.55	816.73	553.4
Minority Interest in Earnings	0.27	0.03	0	-	-	-
Net Income	1,074	1,055	989.17	955.55	816.73	553.4
Net Income to Common	1,074	1,055	989.17	955.55	816.73	553.4
Net Income Growth	-9.26%	6.69%	3.52%	17.00%	47.58%	49.34%
Shares Outstanding (Basic)	1,166	1,169	1,174	1,179	1,179	1,178
Shares Outstanding (Diluted)	1,166	1,169	1,174	1,179	1,179	1,178
Shares Change (YoY)	-0.33%	-0.40%	-0.38%	-0.00%	0.01%	-0.02%
EPS (Basic)	0.92	0.90	0.84	0.81	0.69	0.47
EPS (Diluted)	0.92	0.90	0.84	0.81	0.69	0.47
EPS Growth	-8.97%	7.12%	3.91%	17.00%	47.57%	49.36%
Free Cash Flow	764.29	400.9	817	-90.18	742.41	1,328
Free Cash Flow Per Share	0.66	0.34	0.70	-0.08	0.63	1.13
Dividend Per Share	0.317	0.317	0.297	0.285	0.243	0.165
Dividend Growth	6.70%	6.70%	4.21%	17.28%	47.27%	50.00%
Gross Margin	23.06%	24.86%	23.42%	26.43%	27.66%	31.91%
Operating Margin	9.27%	9.39%	8.60%	10.73%	10.45%	8.37%
Profit Margin	8.75%	9.20%	9.38%	10.69%	10.37%	7.67%
Free Cash Flow Margin	6.23%	3.49%	7.75%	-1.01%	9.42%	18.42%
EBITDA	1,812	1,631	1,296	1,318	1,168	957
EBITDA Margin	14.78%	14.21%	12.29%	14.74%	14.82%	13.27%
D&A For EBITDA	675.51	552.9	389.43	358.64	344.06	353.55
EBIT	1,137	1,078	906.8	959.39	823.59	603.45
EBIT Margin	9.27%	9.39%	8.60%	10.73%	10.45%	8.37%
Effective Tax Rate	12.00%	12.40%	2.26%	14.23%	15.03%	12.68%
Revenue as Reported	12,264	11,474	10,545	8,943	7,880	7,211
Advertising Expenses	-	9.67	1.61	1.86	2.96	7.39

Source: S&P Capital IQ. Standard template. Financial Sources.